Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Still Looking To Buy A Tax Advantage – And Before Congress Flips

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer is willing to make a “bold” M&A move, including one that will improve the company’s tax situation, CEO Ian Read told Q3 earnings call, despite the US government’s initiatives to curb tax inversion deals.

You may also be interested in...



Pfizer Oncology Strategy: An Investment Starts To Pay Off

With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.

When It Comes To A COVID-19 Vaccine For Kids, It Will Be Awhile

US FDA will be cautious about development of a COVID-19 vaccine for children, Commissioner Hahn says at the Financial Times US Pharma And Biotech Summit.

Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold

The US FDA appears to have concerns about the device used to administer the vaccine.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel